- Home
- BIIB vs EME Comparison
BIIB vs EME Comparison
Compare BIIB & EME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- EME
- Stock Information
- Founded
- BIIB 1978
- EME 1987
- Country
- BIIB United States
- EME United States
- Employees
- BIIB N/A
- EME N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- EME Engineering & Construction
- Sector
- BIIB Health Care
- EME Industrials
- Exchange
- BIIB Nasdaq
- EME Nasdaq
- Market Cap
- BIIB 18.8B
- EME 23.9B
- IPO Year
- BIIB 1991
- EME N/A
- Fundamental
- Price
- BIIB $127.50
- EME $549.63
- Analyst Decision
- BIIB Buy
- EME Buy
- Analyst Count
- BIIB 27
- EME 5
- Target Price
- BIIB $188.17
- EME $518.40
- AVG Volume (30 Days)
- BIIB 1.2M
- EME 453.2K
- Earning Date
- BIIB 07-31-2025
- EME 07-24-2025
- Dividend Yield
- BIIB N/A
- EME 0.18%
- EPS Growth
- BIIB 26.39
- EME 49.21
- EPS
- BIIB 10.12
- EME 22.63
- Revenue
- BIIB $9,816,400,000.00
- EME $15,001,212,000.00
- Revenue This Year
- BIIB N/A
- EME $14.16
- Revenue Next Year
- BIIB N/A
- EME $5.76
- P/E Ratio
- BIIB $12.69
- EME $24.33
- Revenue Growth
- BIIB 1.59
- EME 14.30
- 52 Week Low
- BIIB $110.04
- EME $319.49
- 52 Week High
- BIIB $236.48
- EME $562.77
- Technical
- Relative Strength Index (RSI)
- BIIB 45.02
- EME 70.21
- Support Level
- BIIB $132.37
- EME $537.11
- Resistance Level
- BIIB $137.84
- EME $553.97
- Average True Range (ATR)
- BIIB 4.12
- EME 13.07
- MACD
- BIIB 0.01
- EME 0.61
- Stochastic Oscillator
- BIIB 25.82
- EME 79.29
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About EME EMCOR Group Inc.
EMCOR Group Inc is a specialty contractor in the United States and a provider of electrical and mechanical construction and facilities services, building services, and industrial services. Its services are provided to a broad range of commercial, technology, manufacturing, industrial, healthcare, utility, and institutional customers through approximately 100 operating subsidiaries. The company's operating subsidiaries are organized into reportable segments: United States mechanical construction and facilities services, which derives key revenue; United States electrical construction and facilities services; United States building services; United States industrial services; and United Kingdom building services. Geographically, its key revenue is derived from the United States.